Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2856-2861

  Ciomei, Marina ^a,b   Croci, Valter ^a   Ciavolella, Antonella ^a   Ballinari, Dario ^a   Pesenti, Enrico ^a  

^a Nerviano Medical Sciences ^*  (Italy)

^b Biology Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; EDOTECARIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAZOLES; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; INDOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 33646733010     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1859     Document Type: Article

References (31)

1. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75.
2. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
3. de Gramont A, Banzi M, Navarro M, et al. Oxaliplatin/ 5-FU/LV in adjuvant colon cancer: results of the international randomized MOSAIC trial. Proc Am Soc Clin Oncol 2003;22:1015A.
4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
5. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
8. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004;4:562-8.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
10. Yoshinari T, Ohkubo M, Fukasawa K, et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999;59:4271-5.
11. Meng LH, Liao ZY, Pommier Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr Top Med Chem 2003;3:305-20.
12. Ohkubo M, Nishimura T, Kawamoto H, et al. Synthesis and biological activities of NB-506 analogues modified at the glucose group. Bioorg Med Chem Lett 2000;10:419-22.
13. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.
14. Rothenberg ML, Blanke CD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 1999;26:632-9.
15. Data on file. Pfizer Inc.: New York (New York): 2005.
16. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998;279:1504-13.
17. Arakawa H, Morita M, Kodera T, et al. In vivo antitumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn J Cancer Res 1999;90:1163-70.
18. Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2- hydroxyl) ethylamino-12,13-dihydro-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a] -pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 2001;48:250-4.
19. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P. Sequence-dependent activity of the irinotecan- 5 FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 1997;73:729-34.
20. Houghton JA, Cheshire PJ, Hallman JD, et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996;2:107-18.
21. Keane TE, El-Galley RE, Sun C, et al. Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system. J Urol 1998;160:252-6.
22. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998;41:385-90.
23. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
24. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-21.
25. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
26. Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 2003;9:5402-8.
27. Louvet C, Coudray AM, Tournigand C, et al. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. Anticancer Drugs 2000;7:579-82.
28. Ma J, Maliepaard M, Nooter K, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998;41:307-16.
29. Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996;7:437-60.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
31. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.